{"id":55825,"date":"2026-01-29T21:42:43","date_gmt":"2026-01-29T13:42:43","guid":{"rendered":"https:\/\/flcube.com\/?p=55825"},"modified":"2026-01-29T21:42:44","modified_gmt":"2026-01-29T13:42:44","slug":"kanghua-to-acquire-nanoribo-in-phased-deal-for-mrna-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55825","title":{"rendered":"Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform"},"content":{"rendered":"\n

Chengdu Kanghua Biological Products Co., Ltd.<\/strong> (SHE: 300841<\/a>) announced a plan to increase capital investment and acquire equity in NanoRibo (Shanghai) Biotechnology Co., Ltd.<\/strong> through a three\u2011phase transaction<\/strong> that will ultimately give Kanghua full ownership of the mRNA vaccine and therapeutics developer. The first phase involves a CNY\u202f120\u202fmillion (USD\u202f17.3\u202fmillion)<\/strong> investment for a 27.2727% stake<\/strong>.<\/p>\n\n\n\n

Transaction Structure & Deal Terms<\/h2>\n\n\n\n
Phase<\/th>Stake Acquired<\/th>Investment Amount<\/th>Timeline<\/th><\/tr><\/thead>
Phase\u202f1<\/strong><\/td>27.2727%<\/td>CNY\u202f120\u202fmillion (USD\u202f17.3\u202fmillion)<\/td>Announced<\/td><\/tr>
Phase\u202f2<\/strong><\/td>51%<\/td>To be disclosed<\/td>Successive<\/td><\/tr>
Phase\u202f3<\/strong><\/td>100%<\/td>To be disclosed<\/td>Ultimate goal<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Company Profile & Technology Platform<\/h2>\n\n\n\n

NanoRibo Bio<\/strong> is a Shanghai\u2011based biotech focused on novel mRNA\u2011based vaccines and therapeutics<\/strong>, boasting a comprehensive platform covering sequence design, delivery systems, and production processes<\/strong>.<\/p>\n\n\n\n

Key Pipeline Asset<\/strong><\/h3>\n\n\n\n